104 related articles for article (PubMed ID: 26003720)
1. New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.
Gatti L; Cassinelli G; Zaffaroni N; Lanzi C; Perego P
Drug Resist Updat; 2015 May; 20():1-11. PubMed ID: 26003720
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
3. Molecular aspects of antitumor effects of a new platinum(IV) drug.
Kaspárková J; Nováková O; Vrána O; Intini F; Natile G; Brabec V
Mol Pharmacol; 2006 Nov; 70(5):1708-19. PubMed ID: 16896071
[TBL] [Abstract][Full Text] [Related]
4. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
5. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
6. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
7. Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.
Cincinelli R; Musso L; Dallavalle S; Artali R; Tinelli S; Colangelo D; Zunino F; De Cesare M; Beretta GL; Zaffaroni N
Eur J Med Chem; 2013 May; 63():387-400. PubMed ID: 23517728
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
11. Novel bis-platinum complexes endowed with an improved pharmacological profile.
Gatti L; Perego P; Leone R; Apostoli P; Carenini N; Corna E; Allievi C; Bastrup U; De Munari S; Di Giovine S; Nicoli P; Grugni M; Natangelo M; Pardi G; Pezzoni G; Singer JW; Zunino F
Mol Pharm; 2010 Feb; 7(1):207-16. PubMed ID: 19919086
[TBL] [Abstract][Full Text] [Related]
12. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
14. Water-soluble platinum phthalocyanines as potential antitumor agents.
Bologna G; Lanuti P; D'Ambrosio P; Tonucci L; Pierdomenico L; D'Emilio C; Celli N; Marchisio M; d'Alessandro N; Santavenere E; Bressan M; Miscia S
Biometals; 2014 Jun; 27(3):575-89. PubMed ID: 24699848
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
17. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
18. Interaction of two second generation platinum antitumor drugs with mouse thymocytes.
Simpkins H; Pearlman LF
Cancer Res; 1986 Mar; 46(3):1433-9. PubMed ID: 3510724
[TBL] [Abstract][Full Text] [Related]
19. DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+.
Balcarová Z; Kaspárková J; Zákovská A; Nováková O; Sivo MF; Natile G; Brabec V
Mol Pharmacol; 1998 May; 53(5):846-55. PubMed ID: 9584210
[TBL] [Abstract][Full Text] [Related]
20. Platinum drugs and DNA repair mechanisms in lung cancer.
Bonanno L; Favaretto A; Rosell R
Anticancer Res; 2014 Jan; 34(1):493-501. PubMed ID: 24403507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
